Regis Management Co buys $1,577,930 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Regis Management Co scooped up 71 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 2, 2016. The investment management firm now holds a total of 29,439 shares of Merck & Co. which is valued at $1,577,930.Merck & Co. makes up approximately 0.34% of Regis Management Co’s portfolio.

Merck & Co. closed down -0.49 points or -0.91% at $53.6 with 1,05,26,340 shares getting traded on Friday. Post opening the session at $53.82, the shares hit an intraday low of $53.06 and an intraday high of $53.97 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Hamlin Capital Management reduced its stake in MRK by selling 17,860 shares or 1.56% in the most recent quarter. The Hedge Fund company now holds 1,130,440 shares of MRK which is valued at $60,591,584. Merck & Co. makes up approx 3.11% of Hamlin Capital Management’s portfolio.Bridges Investment Management Inc reduced its stake in MRK by selling 1,331 shares or 4.72% in the most recent quarter. The Hedge Fund company now holds 26,882 shares of MRK which is valued at $1,525,285. Merck & Co. makes up approx 0.27% of Bridges Investment Management Inc’s portfolio.Hartford Financial Management boosted its stake in MRK in the latest quarter, The investment management firm added 103 additional shares and now holds a total of 28,749 shares of Merck & Co. which is valued at $1,631,218. Merck & Co. makes up approx 0.98% of Hartford Financial Management’s portfolio.Private Trust Co Na boosted its stake in MRK in the latest quarter, The investment management firm added 1,290 additional shares and now holds a total of 62,558 shares of Merck & Co. which is valued at $3,549,541. Merck & Co. makes up approx 0.95% of Private Trust Co Na’s portfolio.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.